Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Breast Neoplasms 2Vaccinia 1Triple Negative Breast Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 47Carboplatin 35Paclitaxel 28Specimen Handling 20Cyclophosphamide 17Capecitabine 16Magnetic Resonance Spectroscopy 15sacituzumab govitecan 13Gemcitabine 13Biopsy 13Taxes 12130-nm albumin-bound paclitaxel 11Albumin-Bound Paclitaxel 9olaparib 8Doxorubicin 8Nivolumab 7fludarabine 6Cisplatin 6eribulin 5atezolizumab 5Radiotherapy 5Docetaxel 5durvalumab 4Immunoglobulin G 4Fulvestrant 4Epirubicin 4Drug Therapy 4Bevacizumab 4veliparib 3toripalimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Biosimilar Pharmaceuticals × 90 days × Clear all
NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Fudan University

Phase 2 Recruiting
160 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡